Ikemura Kenji, Nakagawa Erika, Kurata Tomohiko, Iwamoto Takuya, Okuda Masahiro
College of Pharmacy, Kinjo Gakuin University.
Drug Metab Pharmacokinet. 2013;28(6):504-9. doi: 10.2133/dmpk.dmpk-13-rg-021. Epub 2013 Jun 18.
The renal tubular secretion of cationic drugs is dominated by basolateral organic cation transporter 2 (rOCT2/SLC22A2) and luminal multidrug and toxin extrusion 1 (rMATE1/SLC47A1). Little is known about the variation in the expression of these renal transporters after liver ischemia-reperfusion (I/R) injury. Here, we examined the pharmacokinetics of a cationic drug, cimetidine, and renal rOCT2 and rMATE1 levels as well as their regulation after liver I/R. Rats were subjected to 60 min of liver ischemia followed by 12 h of reperfusion. The antioxidant Trolox was administered intravenously 5 min before reperfusion. The systemic and tubular secretory clearances of cimetidine (78% and 55%) as well as renal rOCT2 and rMATE1 levels (67% and 61%) in I/R rats were decreased compared with those in sham-operated rats, respectively. However, the renal tissue-to-plasma concentration ratio but not the renal tissue-to-urine clearance ratio of cimetidine was decreased after liver I/R. Moreover, Trolox prevented the decreases in renal rOCT2 levels and systemic clearance of cimetidine after liver I/R. These results demonstrate that liver I/R decreases the tubular secretion of cimetidine, mainly because of the decreased rOCT2 level in the kidney, and that oxidative stress should be responsible in part for decreased renal rOCT2 after liver I/R injury.
阳离子药物的肾小管分泌主要由基底外侧有机阳离子转运体2(rOCT2/SLC22A2)和管腔多药及毒素外排蛋白1(rMATE1/SLC47A1)介导。关于肝脏缺血再灌注(I/R)损伤后这些肾脏转运体表达的变化,目前所知甚少。在此,我们研究了阳离子药物西咪替丁的药代动力学、肾脏rOCT2和rMATE1水平及其在肝脏I/R后的调节情况。对大鼠进行60分钟的肝脏缺血,随后再灌注12小时。在再灌注前5分钟静脉注射抗氧化剂曲洛烯。与假手术大鼠相比,I/R大鼠中西咪替丁的全身清除率和肾小管分泌清除率(分别为78%和55%)以及肾脏rOCT2和rMATE1水平(分别为67%和61%)均降低。然而,肝脏I/R后西咪替丁的肾组织与血浆浓度比降低,但肾组织与尿液清除率比未降低。此外,曲洛烯可防止肝脏I/R后肾脏rOCT2水平降低以及西咪替丁的全身清除率降低。这些结果表明,肝脏I/R降低了西咪替丁的肾小管分泌,主要原因是肾脏中rOCT2水平降低,并且氧化应激在肝脏I/R损伤后肾脏rOCT2降低中应承担部分责任。